Compass Pathways Opened First U.S. Office in Jersey City
The biotech firm chose Jersey City to support its psilocybin-based treatment research.
Updated on Oct. 5, 2026 in Biotech
Live Poll
Do you support the integration of synthetic psychedelic drugs into standard, insurance-covered medical healthcare?
Compass Pathways has officially opened its new U.S. office at 30 Montgomery St. in Jersey City. The company is developing COMP360, a synthetic psilocybin drug designated by the FDA as a Breakthrough Therapy.
Why it matters
The company established this local footprint to leverage the regional life sciences healthcare community. Leaders hope this expansion will further grow the life sciences sector in the Jersey City area.
The COMP360 treatment protocol involves a six-hour supervised session with a psychiatrist, with sessions intended to occur one to three times annually. The firm is currently operating out of suite 340 at 30 Montgomery St.
The players
Compass Pathways
This biotechnology company focuses on developing synthetic psilocybin treatments for mental health conditions.
Hackensack Meridian Health
This is a prominent healthcare network in New Jersey that is collaborating with Compass Pathways on clinical efforts.
Nick Scutari
He is the New Jersey State Senate President who has championed legislation regarding psilocybin in the state.
Peter Thiel
He is a prominent venture capitalist and investor who maintains a minority ownership stake in Compass Pathways.
The details
Compass Pathways is collaborating with Hackensack Meridian Health to prepare for clinical deployment. While clinic treatments are on the horizon, the company still needs to negotiate coverage with Medicare, Medicaid, and private insurers.
Timeline
October 5, 2026: Compass Pathways opened their Jersey City office.
Early 2027: Clinic treatments are expected to begin.
The Tech Race
This move marks a shift in the biotechnology landscape toward integrating psychedelic compounds into traditional psychiatric clinical workflows. It follows the FDA Breakthrough Therapy designation process to expedite the development and review of drugs for serious conditions.
Residents may see an increase in local life sciences employment opportunities as the firm scales its operations. For patients, the eventual rollout of these sessions will depend on upcoming negotiations regarding insurance and Medicare coverage.
The takeaway
The company's expansion highlights the growing institutional interest in integrating synthetic psychedelic therapies into standard psychiatric practice. Future availability will depend heavily on the company's ability to secure broad insurance and public health coverage.
What happens next
Clinical treatments for patients are expected to begin in early 2027.
Further reading
Learn more about the latest developments in the Biotech sector.
Source note: This article includes information reported by Hudson County View.
Live Poll
Do you support the integration of synthetic psychedelic drugs into standard, insurance-covered medical healthcare?
